ProMIS Neurosciences Inc. Cash Flow Conversion Efficiency
ProMIS Neurosciences Inc. cash flow conversion efficiency. Based on the latest financial reports, ProMIS Neurosciences Inc. (PMN) has a cash flow conversion efficiency ratio of -1.108x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.18 Million) by net assets ($9.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ProMIS Neurosciences Inc. (2005–2024)
Cash flow conversion efficiency of ProMIS Neurosciences Inc. from 2005 to 2024. This chart illustrates how ProMIS Neurosciences Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View ProMIS Neurosciences Inc. share price for real-time trading data and today's change.
ProMIS Neurosciences Inc. Cash Flow Conversion Ratio Explained
ProMIS Neurosciences Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ProMIS Neurosciences Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProMIS Neurosciences Inc. ranked by their cash flow conversion efficiency. Also see market value of ProMIS Neurosciences Inc. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GLG Corp Ltd
AU:GLE
|
0.125x |
|
Tigi Ltd
TA:TIGI
|
-1.090x |
|
Ascelia Pharma AB (publ)
ST:ACE
|
-0.137x |
|
Ensysce Biosciences Inc
NASDAQ:ENSC
|
1.767x |
|
TME Pharma N.V.
PA:ALTME
|
0.353x |
|
Mount Burgess Mining NL
AU:MTB
|
0.097x |
|
Kumpulan Jetson Bhd
KLSE:9083
|
0.081x |
|
Raiden Resources Ltd
AU:RDN
|
-0.052x |
Annual Cash Flow Conversion Efficiency for ProMIS Neurosciences Inc. (2005–2024)
The table below shows the annual cash flow conversion efficiency of ProMIS Neurosciences Inc. from 2005 to 2024. Review ProMIS Neurosciences Inc. free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $16.49 Million | $-27.18 Million | -1.649x | +42.94% |
| 2023-12-31 | $3.75 Million | $-10.84 Million | -2.889x | -130.95% |
| 2022-12-31 | $-1.82 Million | $-17.03 Million | 9.335x | +807.56% |
| 2021-12-31 | $7.16 Million | $-9.44 Million | -1.319x | -130.78% |
| 2020-12-31 | $-1.02 Million | $-4.35 Million | 4.286x | +128.02% |
| 2019-12-31 | $398.12K | $-6.09 Million | -15.296x | -178.69% |
| 2018-12-31 | $1.16 Million | $-6.35 Million | -5.489x | -85.69% |
| 2017-12-31 | $1.53 Million | $-4.53 Million | -2.956x | +89.16% |
| 2016-12-31 | $69.43K | $-1.89 Million | -27.258x | -1342.39% |
| 2015-12-31 | $599.98K | $-1.13 Million | -1.890x | -123.02% |
| 2013-12-31 | $-198.23K | $-1.63 Million | 8.209x | -11.47% |
| 2012-12-31 | $-212.54K | $-1.97 Million | 9.273x | -14.15% |
| 2011-12-31 | $-216.25K | $-2.34 Million | 10.801x | +100.38% |
| 2010-12-31 | $809.08 | $-2.31 Million | -2856.656x | -337161.87% |
| 2009-12-31 | $4.67 Million | $-3.96 Million | -0.847x | -0.91% |
| 2008-12-31 | $3.90 Million | $-3.27 Million | -0.839x | -31.21% |
| 2007-12-31 | $8.45 Million | $-5.40 Million | -0.640x | -165.09% |
| 2006-12-31 | $12.20 Million | $-2.94 Million | -0.241x | +17.15% |
| 2005-12-31 | $4.55 Million | $-1.32 Million | -0.291x | -- |
About ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product c… Read more